A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)
Trial details
- Registry ID
- NCT04439071
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
Also recorded as Standard of care
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)NCT04439071 | PTC Therapeutics | Phase 2, Phase 3 | Terminated | 2022-07-20Actual |
| Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI)NCT02501018 | LSTA | Phase 2 | Completed | 2022-05-19Actual |
| A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid TumorsNCT07749586 | ARVN | Phase 1, Phase 2 | Recruiting | 2031-03-31Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |